HBM Sells Swixx Biopharma to SK Capital for €1.5bn
Swiss-listed HBM Healthcare Investments has agreed to sell a majority stake in Swixx Biopharma, a specialised distributor of rare diseases, prescription and over the counter medicinal products to US-based SK Capital Partners. This marks a strategic milestone for both parties as the pharma commercialisation platform accelerates global expansion. The transaction, valued at over €1.5bn, will see HBM, Swixx’s founders, and co-investors…
Tertianum to acquire Senevita from Emeis in €270m deal
Switzerland-based senior living and care specialist Tertianum has agreed to buy Emeis’s Swiss nursing-home arm Senevita for about CHF 250m (around €270m). The transaction has already been cleared by the Swiss Competition Commission (COMCO) and slated to close in the first quarter of 2026, subject to customary conditions and workforce consultations. The sale advances Emeis’s accelerated disposal programme, which has…